Scientific Publications

Advancing dermatological science.

March 2026 Featured

Pediatric Dermatology

Roflumilast Cream, 0.05%, for Atopic Dermatitis in Children 2-5 The INTEGUMENT-OLE Phase 3 Trial

May 2025 Featured

JAMA Dermatology

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body The ARRECTOR Phase 3 Randomized Clinical Trial

September 2024 Featured

JAMA Dermatology

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials

May 2026

SID

Once-daily Roflumilast Cream or Foam 0.3% for the Treatment of Psoriasis in Patients With Diverse Skin Types: Subgroup Analysis From the Phase 3 DERMIS-1/2 and ARRECTOR Trials

May 2026

American Journal of Clinical Dermatology

Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium

January 2026

Winter Clinical Dermatology Conference

Once-daily Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Patients Aged 2–5 Years With Diverse Skin Types: Subgroup Analysis From the Phase 3 INTEGUMENT-PED Trial

December 2025

J Clin Aesthet Dermatol

PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology

November 2025

American Journal of Clinical Dermatology

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks

August 2025

Pediatric Dermatology

Early evidence of safety, clinical benefit, and PK of roflumilast cream 0.3% once daily in children 2–11 (psoriasis)

February 2025

Pediatric Dermatology

Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric AD age 2–5 (INTEGUMENT-PED)

January 2025

Dermatitis

Long-term safety & efficacy with roflumilast cream 0.15% (≥6y, open-label extension)

November 2024

J Invest Dermatol

Chemical, biochemical, and structural similarities/differences of dermatological cAMP PDE-IV inhibitors

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download